Shares of Biocon jumped over 3 per cent in Tuesday's trade after the drug maker informed BSE that that USFDA has completed the audit of its facility in Andhra Pradesh without any observation.
Following the development, the stock jumped 3.62 per cent to hit a high of Rs 370 on BSE.
The company on Monday post market hours said that the US drug regulator had inspected its active pharmaceutical ingredients (API) manufacturing facility in Visakhapatnam during September 11-15.
Read more at:
No comments:
Post a Comment